RBC Capital Maintains Outperform on Biohaven, Lowers Price Target to $22

Benzinga Newsdesk www.benzinga.com Negative 93.4%

Neg 93.4% Neu 0% Pos 0%

RBC Capital analyst Leonid Timashev maintains Biohaven (NYSE:BHVN) with a Outperform and lowers the price target from $23 to $22.